Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Azarnoff

Showing results (31-40 of 116) with videos related to

Pageof 12
Sort By:
Clinical Pharmacokinetics|January 1, 1978
Clinical pharmacokinetics of methotrexateD D Shen, D L Azarnoff
Biomedical Mass Spectrometry|February 1, 1978
Identification of methotrexate and folic acid analogs by mass spectrometryC E Hignite, D L Azarnoff
Annals of the New York Academy of Sciences|January 1, 1984
Drug development: risks and problemsD L Azarnoff, R L Herting
The Medical Clinics of North America|September 1, 1973
Clinical complications of corticosteroid therapy. A selected reviewC A Dujovne, D L Azarnoff
Clinical Pharmacology and Therapeutics|May 1, 1972
Serum digitoxin in uremic patientsD W Shoeman, D L Azarnoff
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 1, 1975
Proceedings: Alterations in the pharmacokinetics of drugs by portocaval shuntR Gugler, P Lain, D L Azarnoff
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1975
Effect of portacaval shunt on the disposition of drugs with and without first-pass effectR Gugler, P Lain, D L Azarnoff
Steroids|March 1, 1976
In vitro inhibition of rat liver cholest-5en-3 beta-ol (cholesterol) biosynthesis by non-mercurial sulfhydryl reagentsD Abernethy, C Hignite, D L Azarnoff
Journal of Pharmacokinetics and Biopharmaceutics|October 1, 1982
Clinical pharmacokinetics of disopyramideA Karim, C Nissen, D L Azarnoff
The American Journal of the Medical Sciences|June 1, 1971
Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamineC Sirtori, A Hurwitz, D L Azarnoff
Pageof 12

Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
Clinical Pharmacokinetics|January 1, 1978
Clinical pharmacokinetics of methotrexateD D Shen, D L Azarnoff
Biomedical Mass Spectrometry|February 1, 1978
Identification of methotrexate and folic acid analogs by mass spectrometryC E Hignite, D L Azarnoff
Annals of the New York Academy of Sciences|January 1, 1984
Drug development: risks and problemsD L Azarnoff, R L Herting
The Medical Clinics of North America|September 1, 1973
Clinical complications of corticosteroid therapy. A selected reviewC A Dujovne, D L Azarnoff
Clinical Pharmacology and Therapeutics|May 1, 1972
Serum digitoxin in uremic patientsD W Shoeman, D L Azarnoff
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 1, 1975
Proceedings: Alterations in the pharmacokinetics of drugs by portocaval shuntR Gugler, P Lain, D L Azarnoff
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1975
Effect of portacaval shunt on the disposition of drugs with and without first-pass effectR Gugler, P Lain, D L Azarnoff
Steroids|March 1, 1976
In vitro inhibition of rat liver cholest-5en-3 beta-ol (cholesterol) biosynthesis by non-mercurial sulfhydryl reagentsD Abernethy, C Hignite, D L Azarnoff
Journal of Pharmacokinetics and Biopharmaceutics|October 1, 1982
Clinical pharmacokinetics of disopyramideA Karim, C Nissen, D L Azarnoff
The American Journal of the Medical Sciences|June 1, 1971
Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamineC Sirtori, A Hurwitz, D L Azarnoff
Pageof 12